Kedrion Biopharma, an international specialist in the manufacture and distribution of plasma-derived therapeutic products used in treating rare and serious diseases, has commenced the CARES10 (Clinical Assessment of phaRmacokinetics, Efficacy, Safety of a 10% Ig) clinical study, it was reported yesterday.
CARES10 is a United States/Canada-based open-label, prospective, multi-centre phase three clinical study to evaluate efficacy, safety and pharmacokinetics of a 10% intravenous immunoglobulin in the treatment of adult patients with primary immunodeficiency diseases (PI).
It is also likely to enrol a limited number of paediatric patients in order to gather preliminary data in that population. To date, 20 patients are enrolled in CARES10. Enrolment will continue until January 2020, with the goal of reaching a total of around 50 patients.
The study is scheduled to be completed by mid-2021.
HUTCHMED doses first patient in global trial of ATTC candidate HMPL-A580
Ensorcell adds new senior leadership team members
Sino Biological launches 2026-2027 Northern Hemisphere influenza vaccine strain antigens
Sanaregen receives FDA clearance for retinal degeneration clinical trial
Lynk Pharmaceuticals reveals positive topline results from zemprocitinib Phase III clinical trial
ReviR Therapeutics doses first participant in First-in-Human Phase 1 clinical trial of RTX-117
Ono Pharmaceutical expands multi-target research collaboration with Congruence Therapeutics
United Therapeutics' ralinepag reduces risk of clinical worsening in pivotal PAH study
Genentech's fenebrutinib meets primary endpoint in pivotal Phase III study for multiple sclerosis
ValiRx establishes animal health subsidiary to target veterinary oncology market